|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33.
2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
NSCLC Meta-analysis Collaborative Group.
Preoperative chemotherapy for non-small-cell lung cancer: A
systematic review and meta-analysis of individual participant data.
Lancet. 383:1561–1571. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yang Y, Luo H, Zheng XL and Ge H: The
optimal immune checkpoint inhibitors combined with chemotherapy for
advanced non-small-cell lung cancer: A systematic review and
meta-analysis. Clin Transl Oncol. 23:1117–1127. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Forde PM, Chaft JE, Smith KN, Anagnostou
V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR,
Broderick S, et al: Neoadjuvant PD-1 blockade in resectable lung
cancer. N Engl J Med. 378:1976–1986. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Provencio M, Nadal E, Insa A,
García-Campelo MR, Casal-Rubio J, Dómine M, Majem M,
Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, et al:
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell
lung cancer (NADIM): An open-label, multicentre, single-arm, phase
2 trial. Lancet Oncol. 21:1413–1422. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable
lung cancer. N Engl J Med. 386:1973–1985. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chaft JE, Oezkan F, Kris MG, Bunn PA,
Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, et
al: Neoadjuvant atezolizumab for resectable non-small cell lung
cancer: An open-label, single-arm phase II trial. Nat Med.
28:2155–2161. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhai H, Li W, Jiang K, Zhi Y and Yang Z:
Neoadjuvant nivolumab and chemotherapy in patients with locally
advanced non-small cell lung cancer: A retrospective study. Cancer
Manag Res. 14:515–524. 2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hu X, Hu C, Liu X, Ma F, Xie J, Zhong P,
Tang C, Fan D, Gao Y, Feng X, et al: Tumor regression rate, PD-L1
expression, pembrolizumab/nab-paclitaxel-based regimens, squamous
cell carcinoma, and comorbidities were independently associated
with efficacy of neoadjuvant chemoimmunotherapy in non-small cell
lung cancer. Front Oncol. 12(1057646)2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Iachina M, Jakobsen E, Møller H,
Lüchtenborg M, Mellemgaard A, Krasnik M and Green A: The effect of
different comorbidities on survival of non-small cells lung cancer
patients. Lung. 193:291–297. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The eighth edition lung cancer stage classification. Chest.
151:193–203. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982.PubMed/NCBI
|
|
14
|
Travis WD, Dacic S, Wistuba I, Sholl L,
Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, et
al: IASLC multidisciplinary recommendations for pathologic
assessment of lung cancer resection specimens after neoadjuvant
therapy. J Thorac Oncol. 15:709–740. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Charlson ME, Pompei P, Ales KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: Development and validation. J Chronic Dis.
40:373–383. 1987.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Colinet B, Jacot W, Bertrand D, Lacombe S,
Bozonnat MC, Daurès JP and Pujol JL: oncoLR health network. A new
simplified comorbidity score as a prognostic factor in
non-small-cell lung cancer patients: Description and comparison
with the Charlson's index. Br J Cancer. 93:1098–1105.
2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Extermann M: Measuring comorbidity in
older cancer patients. Eur J Cancer. 36:453–471. 2000.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Paleri V and Wight RG: Applicability of
the adult comorbidity evaluation-27 and the Charlson indexes to
assess comorbidity by notes extraction in a cohort of United
Kingdom patients with head and neck cancer: A retrospective study.
J Laryngol Otol. 116:200–205. 2002.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Shieh SH, Probst JC, Sung FC, Tsai WC, Li
YS and Chen CY: Decreased survival among lung cancer patients with
co-morbid tuberculosis and diabetes. BMC Cancer.
12(174)2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Heuvers ME, Aerts JGJV, Hegmans JP,
Veltman JD, Uitterlinden AG, Ruiter R, Rodenburg EM, Hofman A,
Bakker M, Hoogsteden HC, et al: History of tuberculosis as an
independent prognostic factor for lung cancer survival. Lung
Cancer. 76:452–456. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Oren O, Yang EH, Molina JR, Bailey KR,
Blumenthal RS and Kopecky SL: Cardiovascular health and outcomes in
cancer patients receiving immune checkpoint inhibitors. Am J
Cardiol. 125:1920–1926. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Criss SD, Palazzo L, Watson TR, Paquette
AM, Sigel K, Wisnivesky J and Kong CY: Cost-effectiveness of
pembrolizumab for advanced non-small cell lung cancer patients with
varying comorbidity burden. PLoS One. 15(e0228288)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhou J, Chao Y, Yao D, Ding N, Li J, Gao
L, Zhang Y, Xu X, Zhou J, Halmos B, et al: Impact of chronic
obstructive pulmonary disease on immune checkpoint inhibitor
efficacy in advanced lung cancer and the potential prognostic
factors. Transl Lung Cancer Res. 10:2148–2162. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shin SH, Park HY, Im Y, Jung HA, Sun JM,
Ahn JS, Ahn MJ, Park K, Lee HY and Lee SH: Improved treatment
outcome of pembrolizumab in patients with nonsmall cell lung cancer
and chronic obstructive pulmonary disease. Int J Cancer.
145:2433–2439. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bochem J, Zelba H, Spreuer J, Amaral T,
Wagner NB, Gaissler A, Pop OT, Thiel K, Yurttas C, Soffel D, et al:
Early disappearance of tumor antigen-reactive T cells from
peripheral blood correlates with superior clinical outcomes in
melanoma under anti-PD-1 therapy. J Immunother Cancer.
9(e003439)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Nabet BY, Esfahani MS, Moding EJ, Hamilton
EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, et
al: Noninvasive early identification of therapeutic benefit from
immune checkpoint inhibition. Cell. 183:363–376.e13.
2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Liu Y, Chen J, Shao N, Feng Y, Wang Y and
Zhang L: Clinical value of hematologic test in predicting tumor
response to neoadjuvant chemotherapy with esophageal squamous cell
carcinoma. World J Surg Oncol. 12(43)2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Vardy JL, Dhillon HM, Pond GR, Renton C,
Clarke SJ and Tannock IF: Prognostic indices of inflammatory
markers, cognitive function and fatigue for survival in patients
with localised colorectal cancer. ESMO Open.
3(e000302)2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wong SK, Nebhan CA and Johnson DB: Impact
of patient age on clinical efficacy and toxicity of checkpoint
inhibitor therapy. Front Immunol. 12(786046)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Shi Y, Chen W, Li C, Zhang Y, Bo M, Qi S
and Li G: Efficacy and safety of first-line treatments with immune
checkpoint inhibitors plus chemotherapy for non-squamous non-small
cell lung cancer: A meta-analysis and indirect comparison. Ann
Palliat Med. 10:2766–2775. 2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Huo G, Liu W and Chen P: Inhibitors of
PD-1 in non-small cell lung cancer: A meta-analysis of clinical and
molecular features. Front Immunol. 13(875093)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
El-Osta H and Jafri S: Predictors for
clinical benefit of immune checkpoint inhibitors in advanced
non-small-cell lung cancer: A meta-analysis. Immunotherapy.
11:189–199. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Abdel-Rahman O: Smoking and EGFR status
may predict outcomes of advanced NSCLC treated with PD-(L)1
inhibitors beyond first line: A meta-analysis. Clin Respir J.
12:1809–1819. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Facchinetti F, Veneziani M, Buti S,
Gelsomino F, Squadrilli A, Bordi P, Bersanelli M, Cosenza A, Ferri
L, Rapacchi E, et al: Clinical and hematologic parameters address
the outcomes of non-small-cell lung cancer patients treated with
nivolumab. Immunotherapy. 10:681–694. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ichiki Y, Taira A, Chikaishi Y, Matsumiya
H, Mori M, Kanayama M, Nabe Y, Shinohara S, Kuwata T, Takenaka M,
et al: Prognostic factors of advanced or postoperative recurrent
non-small cell lung cancer targeted with immune check point
inhibitors. J Thorac Dis. 11:1117–1123. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Banna GL, Friedlaender A, Tagliamento M,
Mollica V, Cortellini A, Rebuzzi SE, Prelaj A, Naqash AR, Auclin E,
Garetto L, et al: Biological rationale for peripheral blood
cell-derived inflammatory indices and related prognostic scores in
patients with advanced non-small-cell lung cancer. Curr Oncol Rep.
24:1851–1862. 2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Mo J, Hu X, Gu L, Chen B, Khadaroo PA,
Shen Z, Dong L, Lv Y, Chitumba MN and Liu J: Smokers or
non-smokers: Who benefits more from immune checkpoint inhibitors in
treatment of malignancies? An up-to-date meta-analysis. World J
Surg Oncol. 18(15)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Charlson ME, Carrozzino D, Guidi J and
Patierno C: Charlson comorbidity index: A critical review of
clinimetric properties. Psychother Psychosom. 91:8–35.
2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zeng X, Zhu S, Xu C, Wang Z, Su X, Zeng D,
Long H and Zhu B: Effect of comorbidity on outcomes of patients
with advanced non-small cell lung cancer undergoing anti-PD1
immunotherapy. Med Sci Monit. 26(e922576)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Jehn CF, Böning L, Kröning H, Pezzutto A
and Lüftner D: Influence of comorbidity, age and performance status
on treatment efficacy and safety of cetuximab plus irinotecan in
irinotecan-refractory elderly patients with metastatic colorectal
cancer. Eur J Cancer. 50:1269–1275. 2014.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Jacot W, Colinet B, Bertrand D, Lacombe S,
Bozonnat MC, Daurès JP and Pujol JL: OncoLR health network. Quality
of life and comorbidity score as prognostic determinants in
non-small-cell lung cancer patients. Ann Oncol. 19:1458–1464.
2008.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Haruki T, Yurugi Y, Wakahara M, Matsuoka
Y, Miwa K, Araki K, Taniguchi Y and Nakamura H: Simplified
comorbidity score for elderly patients undergoing thoracoscopic
surgery for lung cancer. Surg Today. 47:718–725. 2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Linn BS, Linn MW and Gurel L: Cumulative
illness rating scale. J Am Geriatr Soc. 16:622–626. 1968.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Firat S, Byhardt RW and Gore E:
Comorbidity and Karnofksy performance score are independent
prognostic factors in stage III non-small-cell lung cancer: An
institutional analysis of patients treated on four RTOG studies.
Radiation therapy oncology group. Int J Radiat Oncol Biol Phys.
54:357–364. 2002.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Firat S, Bousamra M, Gore E and Byhardt
RW: Comorbidity and KPS are independent prognostic factors in stage
I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys.
52:1047–1057. 2002.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Castro MAF, Dedivitis RA and Ribeiro KCB:
Comorbidity measurement in patients with laryngeal squamous cell
carcinoma. ORL J Otorhinolaryngol Relat Spec. 69:146–152.
2007.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Honecker F, Harbeck N, Schnabel C, Wedding
U, Waldenmaier D, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller
L, et al: Geriatric assessment and biomarkers in patients with
metastatic breast cancer receiving first-line mono-chemotherapy:
Results from the randomized phase III PELICAN trial. J Geriatr
Oncol. 9:163–169. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Yang Y: Enhancing doxorubicin efficacy
through inhibition of aspartate transaminase in triple-negative
breast cancer cells. Biochem Biophys Res Commun. 473:1295–1300.
2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Kang M, Yu J, Sung HH, Jeon HG, Jeong BC,
Park SH, Jeon SS, Lee HM, Choi HY and Seo SI: Prognostic impact of
the pretreatment aspartate transaminase/alanine transaminase ratio
in patients treated with first-line systemic tyrosine kinase
inhibitor therapy for metastatic renal cell carcinoma. Int J Urol.
25:596–603. 2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Sun J, Zhou G, Xie X, Gu W, Huang J, Zhu
D, Hu W, Hou Q, Shi C, Li T, et al: Efficacy and safety of
drug-eluting beads transarterial chemoembolization by
callispheres® in 275 hepatocellular carcinoma patients:
Results from the Chinese callispheres® transarterial
chemoembolization in liver cancer (CTILC) study. Oncol Res.
28:75–94. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Paleri V, Wight RG, Silver CE, Haigentz M
Jr, Takes RP, Bradley PJ, Rinaldo A, Sanabria A, Bień S and Ferlito
A: Comorbidity in head and neck cancer: A critical appraisal and
recommendations for practice. Oral Oncol. 46:712–719.
2010.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Yutaka Y, Sonobe M, Kawaguchi A, Hamaji M,
Nakajima D, Ohsumi A, Menju T, Chen-Yoshikawa TF, Sato T and Date
H: Prognostic impact of preoperative comorbidities in geriatric
patients with early-stage lung cancer: Significance of sublobar
resection as a compromise procedure. Lung Cancer. 125:192–197.
2018.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Mayr R, May M, Martini T, Lodde M, Pycha
A, Comploj E, Wieland WF, Denzinger S, Otto W, Burger M and
Fritsche HM: Predictive capacity of four comorbidity indices
estimating perioperative mortality after radical cystectomy for
urothelial carcinoma of the bladder. BJU Int. 110:E222–E227.
2012.PubMed/NCBI View Article : Google Scholar
|
